Shares of biotech Bluebird are bouncing back after a misreading of clinical data sent the stock into a 2 day selloff. Bullish base is about to break to upside.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
